arrow
P

Paresh Vyas

University of Oxford
H指数:93
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome
Leukemia
IF13.4
2026-07-210
OA
Human haematopoietic stem cells remember inflammatory stress

人类造血干细胞能够记忆炎症应激

Nature
IF48.5
2026-05-270
OAAI
Initial leukemic epigenomic state determines hypomethylating agent response

初始白血病表观基因组状态决定去甲基化药物的反应

2026-05-010
PRE
MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia

MYB活性驱动急性淋巴细胞白血病中增强子的涌现激活和增强子-启动子相互作用

Blood
IF23.1
2026-03-230
PRE
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

早期造血细胞群内的快速克隆选择预示ivosidenib联合治疗的结局

Blood
IF23.1
2025-11-070
PRE
Detecting and quantifying clonal selection in somatic stem cells

检测和量化体干细胞中的克隆选择

2025-07-030
OA
Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome

Down综合征儿童中前白血病性体细胞GATA1突变的临床意义

Blood
IF23.1
2025-06-270
OA
A revised prognostic model for patients with acute myeloid leukemia and first relapse

针对急性髓系白血病首次复发的修订型预后模型

2025-05-260
OA
Clonal tracing with somatic epimutations reveals dynamics of blood ageing

利用体细胞表观突变进行克隆追踪揭示了血液衰老的动态过程

NATURE
IF48.5
2025-05-210
OA
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Bleximenib剂量优化及携带KMT2A和NPM1基因变异的复发/难治性急性白血病患者1期研究的RP2D确定

BLOOD
IF23.1
2024-11-055
PRE
Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo

急性髓系白血病(AML)患者接受magrolimab联合venetoclax和azacitidine治疗与安慰剂治疗的突变景观和应答深度比较

BLOOD
IF23.1
2024-11-051
PRE
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging

突变干细胞在人类克隆造血中的选择性优势与对炎症和衰老的反应减弱有关

2024-08-016
OAAI
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia
2024-01-011
OAAI
Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines
2023-10-013
PRE
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023-04-2651
OA